Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has
reached the halfway mark (1,600 patients) in the enrollment of its landmark
clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay
Impact on Thrombosis And Safety). The trial is specifically designed to
demonstrate the value of providing clinicians with actionable information for
patients who are poor responders to clopidogrel (Plavix(R)). The
multi-center, placebo controlled trial will determine whether tailored
antiplatelet therapy for poor responders, identified based on the results of
the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse
events (e.g., heart attack, stent thrombosis) following percutaneous coronary
intervention (PCI). Currently the trial is being conducted at more than 70
sites in the U.S. and Canada, with a total enrollment goal of approximately
2,800 patients.

"We are thrilled to have reached the halfway point for enrollment in our
GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and
Regulatory Affairs of Accumetrics, Inc. "Once complete, GRAVITAS will be the
largest multi-center clinical trial that links testing with personalized
medicine and improved patient outcomes. We continue our commitment to
ensuring that the VerifyNow System is shown to be an integral tool in
optimizing the use of antiplatelet therapy."

About GRAVITAS
The concept of variability in response to antiplatelet therapy has been well
established. Also being demonstrated with increased frequency is the question
of whether poor response to antiplatelet therapy, based on a laboratory test,
leads to poor patient outcomes. However, Accumetrics recognizes the need for
a study specifically designed to demonstrate the value of providing clinicians
with actionable information to improve outcomes for those patients who are
poor responders to antiplatelet therapy. As a result, the GRAVITAS study is
the first multi-center, placebo-controlled study to determine whether tailored
antiplatelet therapy based on the results of the company's VerifyNow System
and P2Y12 Test reduces major cardiovascular adverse events post-PCI. The
trial is being coordinated by Scripps Advanced Clinical Trials.

About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic tests
for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for
measuring an individual's response to multiple antiplatelet agents. Addressing
every major antiplatelet drug, including EC-cleared product for prasugrel and
FDA-cleared products for aspirin, Plavix, ReoPro(R), and Integrilin(R), the
VerifyNow System provides a valuable tool to help physicians make informed
treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics,
Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a
registered trademark of Millennium Pharmaceuticals. Plavix is a registered
trademark of sanofi-aventis.

CONTACT:
Jules Abraham
Lippert/Heilshorn & Associates
212-838-3777
jabraham@lhai.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

SOURCE Accumetrics, Inc.

Jules Abraham of Lippert/Heilshorn & Associates, +1-212-838-3777,
jabraham@lhai.com, for Accumetrics, Inc.; or Timothy I. Still, President and
CEO of Accumetrics, +1-858-404-8260, press@accumetrics.com